ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112

Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, B-Cell, led by 2 companies.

Furthest: phase 2, since Aug 12, 20264 company-led studies, 4 open or runningNext primary completion: Dec 30, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CRISPR Therapeutics22 open or runningphase 2since Aug 12, 2026Mar 25, 2025Dec 30, 2029phase 2 · NCT07804004
CRISPR Therapeutics22 open or runningphase 2since Nov 30, 2022Nov 30, 2022Jan 2030phase 2 · NCT05643742

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 2 study in Lymphoma, B-CellNew to CRISPR TherapeuticsCRISPR Therapeutics · NCT05643742 · 120 planned · United States, Australia
  2. Mar 25, 2025CRISPR Therapeutics’ first study: phase 1 study in Lupus Erythematosus, SystemicNew to CRISPR TherapeuticsCRISPR Therapeutics · NCT06925542 · 80 planned · United States, Germany, Spain
  3. Apr 8, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicCRISPR Therapeutics · NCT07549698 · 60 planned · United States, Germany, Spain
  4. Aug 12, 2026Phase 2 study in Multiple Sclerosis, Chronic ProgressivePhase 2 reachedCRISPR Therapeutics · NCT07804004 · 220 planned

Ahead

  1. Dec 30, 2029Primary completion: phase 2 study in Multiple Sclerosis, Chronic ProgressiveCRISPR Therapeutics · NCT07804004
  2. Jan 2030Primary completion: phase 2 study in Lymphoma, B-CellCRISPR Therapeutics · NCT05643742
  3. Dec 31, 2031Primary completion: phase 1 study in Lupus Erythematosus, SystemicCRISPR Therapeutics · NCT06925542
  4. Dec 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicCRISPR Therapeutics · NCT07549698

TargetBeta

CD19 →read by rule
“A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited with the clustered regularly interspaced short palindromic repeats (”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07804004Multiple Sclerosis, Chronic Progressive2Not yet recruitingCRISPR TherapeuticsDec 30, 2029220
NCT07549698Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Spain2RecruitingCRISPR TherapeuticsDec 203360
NCT06925542Lupus Erythematosus, Systemic · United States, Germany, Spain1RecruitingCRISPR TherapeuticsDec 31, 203180
NCT05643742Lymphoma, B-Cell · United States, Australia2RecruitingCRISPR TherapeuticsJan 2030120

How it is read

Names in the registry

  • “CTX112”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.